Company
Company
Resilience Biosciences is a clinical-stage biopharmaceutical company located in the AdMare Innovation Centre on the UBC campus in Vancouver, Canada.
Founded by internationally-renowned scientists and medical professionals, RBI builds on two decades of translational neuroscience research at the University of British Columbia and long-standing international clinical partnerships.
Mission
RBI is committed to developing non-opioid, evidence-based, herbal and small-molecule therapeutics to help address global public health challenges related to opioid withdrawal, associated pain, and cognitive impairment.
Approach
Our multidisciplinary approach combines:
- Brain mechanisms underlying addiction, pain, and cognitive deficits
- Reverse translation of clinical insights from traditional herbal medicine
- Rational drug design, modern phyto- and synthetic chemistry
- Rigorous, patient-centered clinical trials
Highly qualified team of preclinical neuroscientists, clinician-researchers, pharma executives, and chemists
Active preclinical and clinical research programs advancing 3 synergistic drug development pipelines
In-house chemistry unit for drug discovery & synthesis